Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conju...
AbbVie And Merck: Defensive Healthcare Plays Providing Income
Healthcare had a mediocre performance in 2023, but it remains a suitable addition to a diversified portfolio due to its defensive characteristics. AbbVie Inc. and Merck & Co., Inc. are attractive h...
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Dividend Stars Every Investor Should Own to Survive a Market Crash
One of the best reasons to invest in dividend stocks is how well they hold up when the stock market falls. Whether it's a correction, a bear market, a recession, a depression or a full-on market cr...
Instead Of Buying A Rolex, I'm Investing $20,000 In These 2 Stocks, Yielding Up To 7%
In this article, I start by explaining why I have decided to refrain from buying a fancy watch. Instead, I decided to invest in two high-yield dividend stocks. As the market valuation has turned un...
7 Dividend Aristocrats That Will Pay You for Years to Come
Dividend Aristocrats are stocks that have been increasing dividends for the last 25 years. Inherently, these companies have deep stability and for that reason continue to be attractive.
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
AbbVie (ABBV) closed at $165.39 in the latest trading session, marking a +0.38% move from the prior day.
7 Highest Yielding Dividend Aristocrats Like AbbVie Are The Best 2024 Ideas Now
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE Ever wanted an extra set of eyes on an investment you're considering?
Final Trades: Verizon, Abbvie, Gilead Sciences and Arch Capital Group
Jenny Harrington, Gilman Hill Asset Management CEO, Jim Lebenthal, chief equity strategist at Cerity Partners, Joe Terranova, senior managing director at Virtus Investment Partners, and Rob Sechan,...
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the preceding trading day.
The 7 Highest Yielding 2024 Dividend Kings To Buy and Hold Forever
Altria owns over 10% of Anheuser-Busch InBev (NYSE: BUD), the world's largest brewer.
Final Trades: Abbvie, Stryker, Crown Castle, Marathon Petroleum
Jim Lebenthal, chief equity strategist at Cerity Partners, Jenny Harrington, Gilman Hill Asset Management CEO, Joe Terranova, senior managing director at Virtus Investment Partners, and Brenda Ving...
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
After underperforming the broad market over the past year, shares of Medtronic offer a 3.4% dividend yield. AbbVie shares offer a juicy 3.8% dividend yield even though the payout has grown 287% ove...
3 Dividend Aristocrats Signal Buy In January With 7 To Watch
"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years."--Kiplinger.com/Investing.
AbbVie Inc. (ABBV) J.P. Morgan 42nd Annual Healthcare Conference
AbbVie Inc. (ABBV) J.P. Morgan 42nd Annual Healthcare Conference
Related Companies